Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: Initial results

World Journal of Gastroenterology

Volumn 14, Issue 29, 2008, Pages 4627-4632

  Sun, Long ^a   Su, Xin Hui ^a   Guan, Yong Song ^b   Pan, Wei Ming ^a   Luo, Zuo Ming ^a   Wei, Ji Hong ^a   Wu, Hua ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

18F flourodeoxyglucose; Follow up; Gastric cancer; Positron emission tomography computed tomography; Recurrence

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; COLLOID CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS CARCINOMA; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MEDICAL DECISION MAKING; METASTASIS; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; STOMACH CANCER; ADENOCARCINOMA; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; STOMACH TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58149186740     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4627     Document Type: Article

References (34)

1. Khalighinejad N, Hariri H, Behnamfar O, Yousefi A, Momeni A. Adenoviral gene therapy in gastric cancer: a review. World J Gastroenterol 2008; 14: 180-184
2. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, Uemura N, Kim JG, Kim N, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351-365
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66
4. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22: 2767-2773
5. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF, Freudenberg LS. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-365
6. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 2006; 20: 597-604
7. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006; 9: 192-196
8. Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6: 46-56
9. Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg 2007; 24: 101-107
10. Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N. Prognostic benefit of extended radical lymphadenectomy for patients with gastric cancer. Anticancer Res 2000; 20: 1285-1289
11. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530
12. Jensen EH, Tuttle TM. Preoperative staging and postoperative surveillance for gastric cancer. Surg Oncol Clin N Am 2007; 16: 329-342
13. Chen CY, Hsu JS, Wu DC, Kang WY, Hsieh JS, Jaw TS, Wu MT, Liu GC. Gastric cancer: preoperative local staging with 3D multi-detector row CT-correlation with surgical and histopathologic results. Radiology 2007; 242: 472-482
14. Kang BC, Kim JH, Kim KW, Lee DY, Baek SY, Lee SW, Jung WH. Value of the dynamic and delayed MR sequence with Gd-DTPA in the T-staging of stomach cancer: correlation with the histopathology. Abdom Imaging 2000; 25: 14-24
15. Shinya S, Sasaki T, Nakagawa Y, Guiquing Z, Yamamoto F, Yamashita Y. The usefulness of diffusion-weighted imaging (DWI) for the detection of gastric cancer. Hepatogastroenterology 2007; 54: 1378-1381
16. Jensen EH, Tuttle TM. Preoperative staging and postoperative surveillance for gastric cancer. Surg Oncol Clin N Am 2007; 16: 329-342
17. Weissleder R. Molecular imaging in cancer. Science 2006; 312: 1168-1171
18. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007; 244: 39-47
19. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med 2006; 57: 99-118
20. Jager PL, de Korte MA, Lub-de Hooge MN, van Waarde A, Koopmans KP, Perik PJ, de Vries EG. Molecular imaging: what can be used today. Cancer Imaging 2005; 5 Spec No A: S27-S32
21. Abhyankar SA, Nair N. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate. Clin Nucl Med 2008; 33: 213-214
22. Tan MC, Castaldo ET, Gao F, Chari RS, Linehan DC, Wright JK, Hawkins WG, Siegel BA, Delbeke D, Pinson CW, Strasberg SM. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables. J Am Coll Surg 2008; 206: 857-868; discussion 868-869
23. Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, Vaylet C, Rougier P, Andre T, Gornet JM, Cherqui D, Delbaldo C, Panis Y, Talbot JN, Meignan M, Le Guludec D. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008; 98: 875-880
24. Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, Ruers TJ. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002; 20: 4453-4458
25. Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 2008; 21: 151-158
26. Sun L, Ye HY, Zhang YH, Guan YS, Wu H. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. World J Gastroenterol 2007; 13: 6115-6118
27. Ruf J, Lopez Hanninen E, Oettle H, Plotkin M, Pelzer U, Stroszczynski C, Felix R, Amthauer H. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005; 5: 266-272
28. Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, Ruers TJ. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002; 20: 4453-4458
29. De Gaetano AM, Calcagni ML, Rufini V, Valenza V, Giordano A, Bonomo L. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging 2008; In Press
30. Pfannenberg AC, Aschoff P, Brechtel K, Muller M, Klein M, Bares R, Claussen CD, Eschmann SM. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol 2007; 80: 437-445
31. Brechtel K, Klein M, Vogel M, Mueller M, Aschoff P, Beyer T, Eschmann SM, Bares R, Claussen CD, Pfannenberg AC. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med 2006; 47: 470-476
32. Fang YH, Muzic RF Jr. Spillover and partial-volume correction for image-derived input functions for small-animal 18F-FDG PET studies. J Nucl Med 2008; 49: 606-614
33. Meave A, Soto ME, Reyes PA, Cruz P, Talayero JA, Sierra C, Alexanderson E. Pre-pulseless Takayasu's arteritis evaluated with 18F-FDG positron emission tomography and gadolinium-enhanced magnetic resonance angiography. Tex Heart Inst J 2007; 34: 466-469
34. Kao PF, Chou YH, Lai CW. Diffuse FDG uptake in acute prostatitis. Clin Nucl Med 2008; 33: 308-310